Outcomes for Optimistic, Neutral and Pessimistic Scenarios after Ten Years of PrEP Implementation

‡Assuming a 100% increase in at-risk behavior. ¶Assuming $700 per person-year of PrEP; the market price of a generic version of tenofovir (Tenvir) manufactured by Cipla in India [87]. §Assuming $318 per person-year of PrEP ($0.87/day); the current cost of manufacturing tenofovir+emtricitabine (Truvada) by Gilead [88]. †Assuming $208 per person-year of PrEP ($0.57/day); the current cost of manufacturing tenofovir (Viread) by Gilead [88]. Costs (defined as drug costs per person-year of PrEP) and health benefits (infections averted) are presented in their undiscounted form for clarity [80]. Costs of PrEP exclude all other costs e.g. drug distribution, pharmacy and clinical services, communications and education, laboratory, treatment of complications including resistance, and counseling. Analyses also exclude the consequences of HIV-1 infection including costs of provision of antiretroviral therapy.